Table 1.
Participants’ characteristics.
| Total number of patients | pwCF (N: 118) n ( %) |
Non-CF subjects (N: 26) n ( %) |
|---|---|---|
| Male sex | 59 (50.0) | 19 (73.1) |
| Age (years), median (range) | 21 (13–38) | 43 (30–76) |
| F508del homozygous | 31 (26.3) | |
| F508del heterozygous | 48 (40.7) | |
| Other variants | 39 (33.1) | |
| Pancreatic insufficiency | 70 (59.3) | |
| Respiratory infection by P. aeruginosa | 54 (45.8) | |
| ppFEV, median (IQR) | 96 (47–129) | |
| ppFEV < 40 | 0 | |
| Oxygen therapy | 0 | |
| Lung transplantation | 0 | |
| Diabetes | 10 (8.5) | |
| Cirrhosis | 4 (3.4) | |
| Inhaled steroids | 59 (50.0) | |
| Systemic steroids | 2 (1.7) | |
| CFTR modulators | 33 (28.0) |
Data are numbers ( %) unless otherwise specified.
CFTR: cystic fibrosis transmembrane conductance regulator. IQR: interquartile range. ppFEV1: percent predicted forced expiratory volume in one second. pwCF: people with cystic fibrosis.